Key result
In acute gadolinium-enhancing MS lesions, approximately 70% of the initially enhancing lesion volume retained stably low MTR over 39 months, with 21% showing remyelination and 9% demyelination.
Population
Multiple sclerosis patients participating in a 3-year Canadian trial assessing immunoablation and autologous…
Design
Cohort
Follow-up
39 months
Authors
Loading...
MTR tracking of MS lesions should not yet change practice; leaves open its role in monitoring prolonged remyelination.
Observational
MTR imaging reveals that demyelination and remyelination follow different temporal evolutions and are ongoing in different lesion regions for at least 3 years after lesion formation in MS.
Chen et al. (2008) conducted an observational in Multiple sclerosis. Acute gadolinium (Gd)-enhancing lesions was evaluated on Changes in magnetization transfer ratio (MTR) consistent with demyelination and remyelination. In acute gadolinium-enhancing MS lesions, approximately 70% of the initially enhancing lesion volume retained stably low MTR over 39 months, with 21% showing remyelination and 9% demyelination.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: